Skip to content
Study details
Enrolling now

Arginine and Whole Brain Radiation Therapy for Brain Metastases

Emory University
NCT IDNCT06328686ClinicalTrials.gov data as of Apr 2026
Phase

EARLY_PHASE1

Target enrollment

10

Study length

about 3.3 years

Ages

18+

Locations

1 site in GA

What this study is about

This trial is testing different ways to give arginine, either by mouth or through a vein, along with whole-brain radiation therapy in people who have cancer that has spread to the brain. The goal is to determine if giving arginine improves how well brain metastases respond to radiation and to find the best way to administer it.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Arginine
  • 2.Receive Whole-Brain Radiotherapy
  • 3.Undergo Biospecimen Collection
  • +3 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized (Open Label)

You are randomly assigned, but you will know your treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

Therapeutic Nutrients/Minerals/Electrolytes (Biological Macromolecular Activity)

Drug routes

oral (Oral Capsule)

Endpoints

Secondary: Incidence of adverse events associated with delivering L-arginine with standard fractionation whole brain radiation therapy

Procedures

diagnostic, imaging, radiation